Breaking AI & Tech News Analyzed

A 47‑year‑old woman who had endured three life‑threatening autoimmune diseases for more than a decade is now living a near‑normal life after an experimental CAR‑T cell therapy reset her immune system at University Hospital Erlangen in Germany.Before the procedure she had exhausted nine different treatments with no lasting benefit, relying on daily blood transfusions and continuous anticoagulation to manage her illnesses.Within weeks of the infusion, doctors observed rapid improvement in all three conditions—a world‑first outcome. She has remained in treatment‑free remission for 14 months and has largely returned to everyday activities.Prof Fabian Müller, who led the team, called the speed and depth of the response “remarkable” and said the therapy “significantly improved her quality of life.” He emphasized that clinical trials are required to determine how durable the effect is and whether it can help other autoimmune patients.The patient suffered from three distinct disorders: autoimmune haemolytic anaemia (AIHA), where rogue immune cells destroy red blood cells; immune thrombocytopenia (ITP), which depletes platelets and raises bleeding risk; and antiphospholipid syndrome (APS), which promotes dangerous blood clots. All three stem from malfunctioning B‑cells.With no conventional options left, doctors turned to CAR‑T therapy, a technique that has revolutionised treatment for certain cancers. They harvested her white‑blood cells, isolated the T‑cells, engineered them to recognise the CD19 protein on B‑cells, and reinfused the modified cells.The engineered T‑cells swiftly eliminated the pathogenic B‑cells. She received her last blood transfusion a week after treatment and was able to perform routine tasks within two weeks. Follow‑up tests showed a reconstituted, healthy B‑cell population, suggesting an immune reset. The findings were published in the journal Med.She still exhibits a mildly low white‑cell count and slightly elevated liver enzymes, which researchers attribute to the cumulative impact of prior therapies rather than the CAR‑T product.Rheumatology expert Prof Ben Parker of Manchester University NHS Foundation Trust described the case as encouraging, noting that “the prolonged response off normal therapy suggests there has been an immune reset.” However, he warned that case reports alone cannot confirm efficacy and highlighted ongoing trials for lupus, myositis, multiple sclerosis, systemic sclerosis, vasculitis, and other autoimmune conditions.

The UK's reliance on glyphosate, a widely used herbicide, has come under fire from campaigners who argue that its use has spiralled out of control. Glyphosate, known for its effectiveness in killing weeds, has been linked to various health risks, including cancer, and environmental damage.Originally pioneered by Scottish farmers in the 1980s to dry crops before harvest, the use of glyphosate has expanded globally. In the UK, over 2,200 tonnes of glyphosate were applied in 2024, with more than half used on wheat and other cereals. This represents a 10-fold increase in usage over the past three decades.Despite the World Health Organization classifying glyphosate as 'probably carcinogenic to humans' in 2015, its use has remained high. Bayer, the manufacturer, maintains that its herbicides do not cause cancer, but this stance is contested by many health and environmental organizations.Campaigners, including Nick Mole of Pesticide Action Network UK, are urging the government to phase out and ultimately ban glyphosate, citing its links to a range of cancers and other life-threatening diseases, as well as its impact on the environment. They argue that safer, more sustainable alternatives are available and should be adopted by farmers and local councils.However, some agricultural experts, like Helen Metcalfe of Rothamsted Research, suggest that glyphosate is used differently in the UK compared to the US, where genetically modified crops are involved. The shift towards 'regenerative' farming practices has contributed to the increased use of glyphosate, as it helps protect soil health and prevent erosion.The debate over glyphosate's safety and environmental impact continues, with the EU banning its use in pre-harvest desiccation in 2023 due to concerns about food accumulation. In the US, Bayer has offered $7.25bn to settle lawsuits alleging that Roundup, which contains glyphosate, can cause cancer. The UK government maintains that pesticide use is strictly regulated and only approved if it does not harm human or animal health or the environment.

Health‑service workers have voiced strong unease after it emerged that engineers from the controversial US tech firm Palantir were issued NHS.net email accounts. Those accounts unlock a directory containing contact details for as many as 1.5 million NHS staff members, as well as access to SharePoint file‑sharing and Microsoft Teams groups used by the service. Palantir’s engineers are supporting the rollout of the Federated Data Platform (FDP), a £300 million contract awarded in 2023 to link patient records across disparate NHS systems. The government touts FDP as a cornerstone of its plan to "reinvent the NHS" by moving from analogue to digital, promising faster diagnoses, better appointment allocation and more personalised treatment. While the use of NHS email accounts by external suppliers is not unprecedented, Palantir’s reputation for AI‑driven surveillance and military‑grade technology has amplified staff, patient and human‑rights concerns. Rory Gibson, a resident doctor, warned that his personal contact details should not be accessible to a company that also works on drone‑strike systems. The Guardian has identified at least six Palantir engineers who have been given NHS.net credentials. In response, a Palantir spokesperson argued that such access is "normal practice for government suppliers" and cited official guidance that government systems are more secure than external alternatives. Palantir claims its software has already yielded measurable benefits: 110,000 additional operations, a 15.3% reduction in discharge delays and a 6.8% rise in cancer diagnoses within 28 days of referral. The company stresses that it merely provides software, with data usage remaining under NHS control and subject to strict contractual confidentiality. David Rowland, director of the Centre for Health and the Public Interest, acknowledged that granting NHS email addresses may not breach rules but highlighted the "deep ethical concerns" that Palantir’s profit‑driven model clashes with NHS values. He called for a comprehensive review of which private firms receive public‑sector funding. Some NHS staff reported being placed in virtual Teams meetings with Palantir personnel who joined using NHS credentials, without any disclosure of their employer – a practice that further eroded trust. Under the NHSmail access policy, "independent sector organisations" delivering health and social‑care services nationally may use NHSmail. An unrestricted NHS.net account can reveal staff roles, locations, workplace details and even grant access to commercial "Blue Light" discounts. Palantir’s technology is already deployed by UK police forces and the Ministry of Defence, prompting critics to warn that its "drag‑and‑drop" interoperability could facilitate state overreach, including a potential British analogue of the US Immigration and Customs Enforcement agency. The firm’s founders include US businessman and former Trump supporter Peter Thiel and CEO Alex Karp, both known for advocating aggressive surveillance tools. Its UK arm is led by Louis Mosley, grandson of historic British fascist leader Oswald Mosley. An NHS spokesperson reiterated that all suppliers, including Palantir, operate strictly under NHS instruction, with data access governed by robust contractual confidentiality obligations.

Mexico is facing a severe 'toxic crisis' due to the importation of hazardous waste from the US, according to a UN expert. Marcos Orellana, the UN special rapporteur on toxics and human rights, conducted an 11-day investigative mission in Mexico and found lax environmental standards and a lack of oversight, leading to the accumulation of pollution over the years. Orellana warned that over 1,000 contaminated locations are officially recorded in Mexico's National Inventory of Contaminated Sites, many of which have become 'sacrifice zones' where diseases such as cancer and medical events like miscarriages are normalized. He cited factories spewing hazardous waste into the Atoyac River in Puebla, huge industrial pig farms contaminating drinking water on the Yucatan peninsula, and a decade-old mining chemical spill affecting health in communities around the Sonora River. The expert emphasized that US overconsumption and economic activity are using Mexico as a 'garbage sink'. He proposed that Mexico could adopt restrictions on the import of hazardous waste as a measure to address part of the crisis. Some countries have chosen to ban such imports to avoid becoming destinations for international waste. Residents in Monterrey, which suffers from some of the worst air pollution in North America, welcomed the rapporteur's calls for more attention to the health of Mexico's people. Local activists and childcare center directors highlighted the dire health effects on communities, including respiratory illnesses and other health issues. Mexico's government has acknowledged that regulatory standards are out of date and has announced plans to strengthen them. Officials are rolling out a new air monitoring system to detect emissions from specific facilities, starting in an industrial corridor of Monterrey.

The Artemis II mission has achieved a remarkable feat, with the crew flying further from Earth than any human before them, reaching a distance of 406,778km (252,760 miles) from Earth. This historic moment broke a 56-year-old record set by the Apollo 13 mission.During their six-hour lunar flyby, the crew captured unprecedented views of the moon's far side, providing a human perspective on features previously only known through robotic photographs. The astronauts used high-powered Nikon cameras and their iPhones to document the lunar surface, with plans to return with thousands of pictures, including images of the Apollo 12 and 14 landing sites.The mission also included an emotional moment when the crew honored the legacy of past astronauts. They began the day with a wake-up message from Jim Lovell, the Apollo 13 commander, who recorded the message two months before his death. Lovell welcomed the crew to 'my old neighborhood' and encouraged them to enjoy the view.In a touching gesture, the astronauts named two fresh lunar craters. They proposed the names Integrity for their capsule and Carroll, in honor of Commander Reid Wiseman's late wife who passed away from cancer in 2020. Wiseman, a former fighter pilot, has been raising their two daughters on his own since then. The names will be passed along to the International Astronomical Union for official designation.The mission's free-return lunar trajectory took advantage of gravity from the Earth and moon, reducing the need for fuel. This figure-of-eight path will put the astronauts on course for home once they emerge from behind the moon. As they passed across the far side of the moon, the capsule experienced a 40-minute communications blackout, a routine occurrence during the Apollo missions.Canadian astronaut Jeremy Hansen challenged future generations to make sure the record broken by Artemis II is not long-lived. The crew's achievements and emotional moments highlight the significance of this mission in the history of space exploration.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Iran’s only operational nuclear power station, the Bushehr plant, has endured a series of assaults amid the escalating Israel‑United States campaign against Tehran, sparking alarm over a possible regional nuclear incident.The most recent strike on Saturday resulted in the death of a security guard and damage to an auxiliary building, according to the state‑run Atomic Energy Organisation of Iran (AEOI).Foreign Minister Abbas Araghchi asserted that the facility has been "bombed" four times since the conflict erupted on 28 February, accusing the United States and Israel of a "lack of concern" for nuclear safety.Security analysts stress that any bombing of the reactor or its spent‑fuel pools would unleash the radioactive isotope Caesium‑137, a contaminant capable of traveling far via wind and water, rendering soil, food and drinking supplies hazardous for decades and increasing cancer risks for exposed populations.The Bushehr complex, built by Russia and completed in 2011, supplies roughly 1,000 MW to Iran’s grid. It is the Middle East’s first nuclear plant and is slated to host two additional reactors by 2029, with hundreds of Russian technicians on site.The International Atomic Energy Agency (IAEA) has repeatedly warned that a direct hit could trigger a “regional catastrophe.” Director‑General Rafael Grossi told the UN Security Council that striking the plant could cause a "very high release of radioactivity" and, if power to the cooling system were cut, could lead to a reactor melt. He called for "maximum restraint," noting that evacuation zones could extend several hundred kilometres, requiring iodine prophylaxis and food‑supply restrictions.Beyond terrestrial fallout, experts highlight the danger of contaminating the Gulf’s shallow waters. Radioactive pollution would devastate marine ecosystems and cripple desalination plants, which lack the technology to filter such material. Qatar’s prime minister, Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani, warned that a simulated Bushehr attack would render the sea "entirely contaminated" and leave the country without water within three days.International law explicitly forbids targeting civilian nuclear installations. Article 56 of Protocol I to the Geneva Conventions bars attacks on "works and installations containing dangerous forces," and the IAEA’s own guidelines prohibit indiscriminate strikes on reactors, fuel storage, or power supplies.Araghchi also criticized the muted Western response, contrasting it with the outcry over Ukraine’s Zaporizhzhia plant, which prompted emergency UN sessions, NATO warnings, and statements from the EU, UK and US. In the Bushehr case, the EU has remained silent, while Russia, which maintains a sizable staff at the site, issued a condemnation of the attacks.Historical precedents such as the 2011 Fukushima disaster and the 1986 Chernobyl explosion illustrate the long‑term human and environmental toll of nuclear accidents, underscoring why the safety of Bushehr is viewed as a matter of regional, not merely national, security.

David Attenborough is set to dazzle audiences with his sparkling new series on BBC One, showcasing the wonders of wildlife living right under our noses. The series begins in Oxfordshire, where Attenborough discovers scampering voles and talking duck eggs.Meanwhile, on Channel 4, The Great Celebrity Bake Off for Stand Up to Cancer challenges celebrities to conjure up mini rolls and syrup sponge puddings, with a showstopper involving recreating their best looks in choux pastry form.Other highlights include The Other Bennet Sister on BBC One, The Capture on BBC One, and Pilgrimage: The Road to Holy Island on BBC Two. Film enthusiasts can look forward to Being There on BBC Two at 11:50pm.For sports fans, Women’s FA Cup Football matches are scheduled on TNT Sports 1 and Channel 4.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”